Details
| Stereochemistry | EPIMERIC |
| Molecular Formula | C18H18N6O5S2.C3H8O2 |
| Molecular Weight | 538.597 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(O)CO.N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSC3=CN=NN3)=C(N2C1=O)C(O)=O)C4=CC=C(O)C=C4
InChI
InChIKey=CKOIKOHDEYTLFR-PFBPGKLMSA-N
InChI=1S/C18H18N6O5S2.C3H8O2/c19-12(8-1-3-10(25)4-2-8)15(26)21-13-16(27)24-14(18(28)29)9(7-31-17(13)24)6-30-11-5-20-23-22-11;1-3(5)2-4/h1-5,12-13,17,25H,6-7,19H2,(H,21,26)(H,28,29)(H,20,22,23);3-5H,2H2,1H3/t12-,13-,17-;/m1./s1
| Molecular Formula | C18H18N6O5S2 |
| Molecular Weight | 462.503 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | C3H8O2 |
| Molecular Weight | 76.0944 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
DescriptionCurator's Comment: Description was created based on several sources, including https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=NCI_Thesaurus&code=C81027 and http://www.ncbi.nlm.nih.gov/pubmed/426514
Curator's Comment: Description was created based on several sources, including https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=NCI_Thesaurus&code=C81027 and http://www.ncbi.nlm.nih.gov/pubmed/426514
Cefatrizine is a broad-spectrum, semisynthetic, first-generation cephalosporin with antibacterial activity. Cefatrizine binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Cefatrizine is used to treat a large variety of bacterial infections, such as respiratory tract, ear, skin and urinary tract infections. Cefatrizine is less effective against gram positive bacteria than first generation drugs. Antibiotics require constant drug level in body for therapeutic effect.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL5026 Sources: http://www.ncbi.nlm.nih.gov/pubmed/26776155 |
|||
Target ID: Bacterial growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/1137381 |
|||
Target ID: map00550 Sources: http://www.kegg.jp/dbget-bin/www_bget?D02406 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | Unknown Approved UseUnknown |
|||
| Curative | Unknown Approved UseUnknown |
|||
| Curative | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Antibiotic Treatment of Dogs and Cats during Pregnancy. | 2010-12-14 |
|
| Pathogen incidence and antibiotic resistance patterns of catheter-associated urinary tract infection in children. | 2009-12 |
|
| Synthesis, characterization, antibacterial and anti-inflammatory activities of enoxacin metal complexes. | 2009 |
|
| Drug absorption modeling as a tool to define the strategy in clinical formulation development. | 2008-09 |
|
| In vitro activity of cefadroxil, cephalexin, cefatrizine and cefpirome in presence of essential and trace elements. | 2007-10 |
|
| Pharmacokinetics of oral cefatrizine in pregnant and non-pregnant women with reference to fetal distribution. | 2007 |
|
| European Surveillance of Antimicrobial Consumption (ESAC): outpatient cephalosporin use in Europe. | 2006-08 |
|
| Simultaneous determination of cefatrizine and clavulanic acid in dog plasma by HPLC. | 2004-04-01 |
|
| [Infective pathogens and drug resistance in burned patients]. | 2003-08 |
|
| The pharmacokinetics of the interstitial space in humans. | 2003-07-30 |
|
| Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients. | 2001-11 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://en.pharmacodia.com/web/drug/1_10470.html
Curator's Comment: Can also be administered i.v. http://www.ncbi.nlm.nih.gov/pubmed/6660858
It is given by mouth as the base or, more commonly, as a compound with propylene glycol, in usual doses equivalent to 500 mg twice daily of cefatrizine.
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/426514
Curator's Comment: Bacterial isolates were from urine, sputum, throat, stool, and wound cultures of
patients. Cefatrizine inhibited the majority of Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Salmonella at concentrations below 12.5 mug/ml.
A total of 90% of isolates were inhibited by 1.6 ug of cefatrizine per ml
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:27:46 GMT 2025
by
admin
on
Mon Mar 31 19:27:46 GMT 2025
|
| Record UNII |
3731IA5GI9
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C357
Created by
admin on Mon Mar 31 19:27:46 GMT 2025 , Edited by admin on Mon Mar 31 19:27:46 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID00972733
Created by
admin on Mon Mar 31 19:27:46 GMT 2025 , Edited by admin on Mon Mar 31 19:27:46 GMT 2025
|
PRIMARY | |||
|
57235-40-2
Created by
admin on Mon Mar 31 19:27:46 GMT 2025 , Edited by admin on Mon Mar 31 19:27:46 GMT 2025
|
NON-SPECIFIC STOICHIOMETRY | |||
|
100000091867
Created by
admin on Mon Mar 31 19:27:46 GMT 2025 , Edited by admin on Mon Mar 31 19:27:46 GMT 2025
|
PRIMARY | |||
|
SUB11797MIG
Created by
admin on Mon Mar 31 19:27:46 GMT 2025 , Edited by admin on Mon Mar 31 19:27:46 GMT 2025
|
PRIMARY | |||
|
64217-62-5
Created by
admin on Mon Mar 31 19:27:46 GMT 2025 , Edited by admin on Mon Mar 31 19:27:46 GMT 2025
|
PRIMARY | |||
|
6410757
Created by
admin on Mon Mar 31 19:27:46 GMT 2025 , Edited by admin on Mon Mar 31 19:27:46 GMT 2025
|
PRIMARY | |||
|
3731IA5GI9
Created by
admin on Mon Mar 31 19:27:46 GMT 2025 , Edited by admin on Mon Mar 31 19:27:46 GMT 2025
|
PRIMARY | |||
|
m3187
Created by
admin on Mon Mar 31 19:27:46 GMT 2025 , Edited by admin on Mon Mar 31 19:27:46 GMT 2025
|
PRIMARY | Merck Index | ||
|
C98215
Created by
admin on Mon Mar 31 19:27:46 GMT 2025 , Edited by admin on Mon Mar 31 19:27:46 GMT 2025
|
PRIMARY | |||
|
260-642-4
Created by
admin on Mon Mar 31 19:27:46 GMT 2025 , Edited by admin on Mon Mar 31 19:27:46 GMT 2025
|
PRIMARY | |||
|
CHEMBL286398
Created by
admin on Mon Mar 31 19:27:46 GMT 2025 , Edited by admin on Mon Mar 31 19:27:46 GMT 2025
|
PRIMARY | |||
|
DBSALT002708
Created by
admin on Mon Mar 31 19:27:46 GMT 2025 , Edited by admin on Mon Mar 31 19:27:46 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ANHYDROUS->SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |